Recent Updates
Recently added Catalysts
MAZE Neutral Sentiment

NOVEMBER 2024 I MAZE THERAPEUTICS

Key Takeaway: The article discusses the privacy overview and cookie usage on the Maze Therapeutics website. It highlights the necessity of cookies for website functionality and user experience. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data to improve the website.

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
1.8%
average across 3 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
MZE829
Phase 2 · Proteinuric Kidney Disease

Full Press Release Details

• Privacy Overview
• Essential Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
These cookies are necessary for our website to function and for measurement purposes. Opt-out rights do not apply to these cookies.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What cookies does Maze Therapeutics use?

Maze Therapeutics uses essential cookies for website functionality and measurement.

How does Maze Therapeutics use Google Analytics?

Google Analytics is used to collect anonymous data about website visitors.

Can I opt-out of cookies on Maze Therapeutics' website?

Opt-out rights do not apply to essential cookies used on the website.

Last updated: Nov 29, 2024